Stryker SYK Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| MedSurg and Neurotechnology: | $15.19B+12.4% | $13.52B+11.1% | $12.16B+11.7% | $10.89B+14.2% | |
| Orthopaedics: | $9.92B+9.3% | $9.08B+8.9% | $8.34B+10.3% | $7.56B-0.2% | |
| Segment operating income by Business | |||||
| MedSurg and Neurotechnology: | $4.46B+11.4% | $4B+15.4% | $3.47B+22.6% | $2.83B+0.9% | |
| Orthopaedics | $3.03B+17.1% | $2.59B+14.4% | $2.27B+2.9% | $2.2B— | |
| Reclassification to: cost of sales by Business | |||||
| MedSurg and Neurotechnology: | $5.71B+7.4% | $5.32B+9.1% | $4.88B+5.2% | $4.64B— | |
| Orthopaedics | $2.72B+13.2% | $2.4B+6.5% | $2.25B+17.4% | $1.92B— | |
| Additions and adjustments by Business | |||||
| MedSurg and Neurotechnology | $3.28B+284% | $852M+183% | $301M-87.0% | $2.32B+940% | |
| Orthopaedics | -$1M-100% | $300M— | $0— | $0-100% | |
| Selling, general and administrative expenses by Business | |||||
| MedSurg and Neurotechnology: | $3.85B+20.3% | $3.2B+9.2% | $2.93B+14.4% | $2.56B— | |
| Orthopaedics | $3.21B+3.2% | $3.11B+6.5% | $2.92B+12.0% | $2.61B— | |
| Research, development and engineering expenses by Business | |||||
| MedSurg and Neurotechnology: | $931M+18.8% | $784M+11.7% | $702M+2.9% | $682M— | |
| Orthopaedics | $542M+0.4% | $540M+6.3% | $508M+6.5% | $477M— | |
| D&A by Business | |||||
| MedSurg and Neurotechnology: | $228M+9.6% | $208M+14.9% | $181M+1.7% | $178M-65.6% | |
| Orthopaedics | $432M-0.2% | $433M+12.2% | $386M+10.3% | $350M— | |
| Foreign exchange and other by Business | |||||
| MedSurg and Neurotechnology | $73M-15.1% | $86M+153% | $34M+163% | -$54M-315% | |
| Orthopaedics | $89M+152% | -$170M-707% | $28M+132% | -$88M+31.8% | |
| Capital Expenditures During Period by Business | |||||
| MedSurg and Neurotechnology: | $220M-20.3% | $276M+50.8% | $183M+4.6% | $175M-11.2% | |
| Orthopaedics | $296M+28.7% | $230M+28.5% | $179M+3.5% | $173M— | |
| Net Sales by Product | |||||
| Endoscopy | $3.81B+12.3% | $3.39B+10.5% | $3.07B+11.2% | $2.76B+14.1% | |
| Hips | $1.87B+9.4% | $1.7B+10.4% | $1.54B+9.3% | $1.41B+5.3% | |
| Instruments | $3.29B+16.1% | $2.83B+11.8% | $2.53B+12.9% | $2.25B+6.3% | |
| Knees | $2.66B+8.5% | $2.45B+7.7% | $2.27B+13.8% | $2B+8.1% | |
| Medical | $4.2B+9.1% | $3.85B+11.4% | $3.46B+14.1% | $3.03B+16.3% | |
| Spine | $185M-73.8% | $707M— | —— | —— | |
| Trauma and Extremities | $3.95B+12.6% | $3.51B+11.4% | $3.15B+12.1% | $2.81B+5.4% | |
| Vascular | $1.97B+50.6% | $1.31B+6.6% | $1.23B+2.2% | $1.2B+1.0% | |
| Net Sales by Geography | |||||
| Asia Pacific | $2.16B+7.1% | $2.02B+3.8% | $1.95B+3.2% | $1.89B-4.5% | |
| Europe, Middle East, Africa | $3.18B+9.8% | $2.9B+10.7% | $2.62B+11.5% | $2.35B+2.1% | |
| International | $6.11B+8.1% | $5.65B+7.8% | $5.24B+8.9% | $4.81B+0.5% | |
| Other foreign countries | $765M+4.1% | $735M+8.6% | $677M+17.1% | $578M+12.2% | |
| United States | $19.01B+12.2% | $16.94B+11.1% | $15.26B+11.9% | $13.64B+10.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stryker break its business down?
- Stryker (SYK) reports net sales by business across 2 parts — MedSurg and Neurotechnology: and Orthopaedics:. Each is extracted from the segment footnotes and tracked over time.
- Where does Stryker's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stryker's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
